Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2012

01.10.2012 | review article

The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease

verfasst von: Saidan Ding, Leping Liu, Qǐ-Chuan Zhuge, Zhen Yu, Xing Zhang, Jieya Xie, Weilong Hong, Silu Wang, Yunxiu Yang, Bicheng Chen, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2012

Einloggen, um Zugang zu erhalten

Summary

Objective

Two common variations of peroxisome proliferator-activated receptor γ (PPARG), P12A (Pro12Ala, rs1801282), and C161T (His447His, rs3856806), are thought to have an effect on susceptibility to coronary heart disease (CHD), but the results are inconsistent. Therefore, a meta-analysis of published studies was performed.

Methods

The electronic databases, PubMed, Embase, Web of Science, and CNKI (China National Knowledge Infrastructure) were searched for studies to include in the present meta-analysis (last search was updated on 30 Aug. 2011). Twenty studies testing the association between PPARG gene polymorphisms and CHD were examined: 12 studies of P12A; 8 studies of C161T. Overall and ethnicity-specific summary odds ratios and corresponding 95 % confidence intervals for CHD associated with these polymorphisms were estimated using fixed- and random-effects models. Heterogeneity and publication bias were evaluated. A total of 20 studies including 5,795 cases and 9,069 controls were included in this meta-analysis.

Results

No significant associations were found in carriers of the rare Ala allele of the P12A polymorphism versus the common Pro/Pro genotype among the studies with both of the fixed-effect and random-effect model. In the subgroup analyses by ethnicity, source of control and type of study, no significant risks were found. For PPARG C161T, carriers of the T variant of C161T polymorphism were associated with an increased risk of CHD (OR = 1.182, 95 % CI: 1.023–1.341, Pheterogeneity = 0.002), and in the stratified analysis by ethnicity and source of controls, the contrast of CT + TT vs. CC all produced significant association in Asian and hospital-based controls (OR = 1.276, 95 % CI: 1.084–1.468, Pheterogeneity = 0.055; OR = 1.164, 95 % CI: 1.001–1.326, Pheterogeneity = 0.002),when the fixed-effect model was used. But they were all insignificant with the random-effect model.

Conclusion

This meta-analysis suggests that the PPARG C161T polymorphism marginally contributes to increased susceptibility to CHD and marginally increased association between PPARG H477H polymorphism and CHD also appeared in Asian and hospital-based controls. But PPARG P12A polymorphism is not associated with CHD risk.
Literatur
1.
Zurück zum Zitat Ashokkumar M, Veera Subhashini NG, Kanthimathi S, et al. Associations for lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in an Indian population. Arch Med Res. 2010;41(1):19–25 e1.PubMedCrossRef Ashokkumar M, Veera Subhashini NG, Kanthimathi S, et al. Associations for lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in an Indian population. Arch Med Res. 2010;41(1):19–25 e1.PubMedCrossRef
2.
Zurück zum Zitat Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Ann Rev Med. 2006;57:313–29.PubMedCrossRef Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Ann Rev Med. 2006;57:313–29.PubMedCrossRef
3.
Zurück zum Zitat Chao TH, Li YH, Chen JH, et al. The 161tt genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci. (Lond) (2004);107(5):461–6.PubMedCrossRef Chao TH, Li YH, Chen JH, et al. The 161tt genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci. (Lond) (2004);107(5):461–6.PubMedCrossRef
4.
Zurück zum Zitat Deeb SS, Fajas L, Nemoto M, et al. A pro12ala substitution in ppargamma2 associated with decreased receptor activity, lower body mass index and improved insulinsensitivity. Nat Genet. 1998;20(3):284–7.PubMedCrossRef Deeb SS, Fajas L, Nemoto M, et al. A pro12ala substitution in ppargamma2 associated with decreased receptor activity, lower body mass index and improved insulinsensitivity. Nat Genet. 1998;20(3):284–7.PubMedCrossRef
5.
Zurück zum Zitat Doney AS, Fischer B, Cecil JE, et al. Association of the pro12ala and c1431t variants of pparg and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 2004;47(3):555–8.PubMedCrossRef Doney AS, Fischer B, Cecil JE, et al. Association of the pro12ala and c1431t variants of pparg and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 2004;47(3):555–8.PubMedCrossRef
6.
Zurück zum Zitat Doney AS, Fischer B, Leese G, et al. Cardiovascular risk in type 2 diabetes is associated with variation at the pparg locus: A go-darts study. Arterioscler Thromb Vasc Biol. 2004;24(12):2403–7.PubMedCrossRef Doney AS, Fischer B, Leese G, et al. Cardiovascular risk in type 2 diabetes is associated with variation at the pparg locus: A go-darts study. Arterioscler Thromb Vasc Biol. 2004;24(12):2403–7.PubMedCrossRef
7.
Zurück zum Zitat Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCrossRef Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCrossRef
8.
Zurück zum Zitat Evangelisti L, Attanasio M, Lucarini L, et al. Ppargamma promoter polymorphisms and acute coronary syndrome. Atherosclerosis 2009;205(1):186–91.PubMedCrossRef Evangelisti L, Attanasio M, Lucarini L, et al. Ppargamma promoter polymorphisms and acute coronary syndrome. Atherosclerosis 2009;205(1):186–91.PubMedCrossRef
9.
Zurück zum Zitat Galgani A, Valdes A, Erlich HA, et al. Homozygosity for the ala allele of the ppargamma2 pro12ala polymorphism is associated with reduced risk of coronary artery disease. Dis Markers. 2010;29(5):259–64.PubMed Galgani A, Valdes A, Erlich HA, et al. Homozygosity for the ala allele of the ppargamma2 pro12ala polymorphism is associated with reduced risk of coronary artery disease. Dis Markers. 2010;29(5):259–64.PubMed
10.
Zurück zum Zitat Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of ppars. Pharmacol Res. 2005;51(2):85–94.PubMedCrossRef Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of ppars. Pharmacol Res. 2005;51(2):85–94.PubMedCrossRef
11.
Zurück zum Zitat Li L, Cheng LX, Nsenga R, et al. Association between pro12ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol. 2006;29(7):300–4.PubMedCrossRef Li L, Cheng LX, Nsenga R, et al. Association between pro12ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol. 2006;29(7):300–4.PubMedCrossRef
12.
Zurück zum Zitat Liu Y, Yuan Z, Zhang J, et al. Ppargamma gene c161t substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J. 2007;154(4):718–24. Liu Y, Yuan Z, Zhang J, et al. Ppargamma gene c161t substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J. 2007;154(4):718–24.
13.
Zurück zum Zitat Masugi J, Tamori Y, Mori H, et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 onthiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268(1):178–82.PubMedCrossRef Masugi J, Tamori Y, Mori H, et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 onthiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268(1):178–82.PubMedCrossRef
14.
Zurück zum Zitat Peng DQ, Zhao SP, Nie S, et al. Gene-gene interaction of ppargamma and apoe affects coronary heart disease risk. Int J Cardiol. 2003;92(2–3):257–63.PubMedCrossRef Peng DQ, Zhao SP, Nie S, et al. Gene-gene interaction of ppargamma and apoe affects coronary heart disease risk. Int J Cardiol. 2003;92(2–3):257–63.PubMedCrossRef
15.
Zurück zum Zitat Pischon T, Pai JK, Manson JE, et al. Peroxisome proliferator-activated receptor-gamma2 p12a polymorphism and risk of coronary heart disease in us men and women. Arterioscler Thromb Vasc Biol. 2005;25(8):1654–8.PubMedCrossRef Pischon T, Pai JK, Manson JE, et al. Peroxisome proliferator-activated receptor-gamma2 p12a polymorphism and risk of coronary heart disease in us men and women. Arterioscler Thromb Vasc Biol. 2005;25(8):1654–8.PubMedCrossRef
16.
Zurück zum Zitat Rhee EJ, Kwon CH, Lee WY, et al. No association of pro12ala polymorphism of ppar-gamma gene with coronary artery disease in Korean subjects. Circ J. 2007;71(3):338–42.PubMedCrossRef Rhee EJ, Kwon CH, Lee WY, et al. No association of pro12ala polymorphism of ppar-gamma gene with coronary artery disease in Korean subjects. Circ J. 2007;71(3):338–42.PubMedCrossRef
17.
Zurück zum Zitat Ridker PM, Cook NR, Cheng S, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (pparg2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23(5):859–63.PubMedCrossRef Ridker PM, Cook NR, Cheng S, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (pparg2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23(5):859–63.PubMedCrossRef
18.
Zurück zum Zitat Ruiz-Narvaez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (pparg) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr. 2007;86(4):1238–42.PubMed Ruiz-Narvaez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (pparg) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr. 2007;86(4):1238–42.PubMed
19.
Zurück zum Zitat Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8(3):159–66.PubMedCrossRef Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8(3):159–66.PubMedCrossRef
20.
Zurück zum Zitat Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-gamma2 pro12ala polymorphism. Diabetes 2002;51(8):2341–7.PubMedCrossRef Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-gamma2 pro12ala polymorphism. Diabetes 2002;51(8):2341–7.PubMedCrossRef
21.
Zurück zum Zitat Vogel U, Segel S, Dethlefsen C, et al. Ppargamma pro12ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009;10:52.PubMedCrossRef Vogel U, Segel S, Dethlefsen C, et al. Ppargamma pro12ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009;10:52.PubMedCrossRef
22.
Zurück zum Zitat Wan J, Xiong S, Chao S, et al. Ppargamma gene c161t substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:13.PubMedCrossRef Wan J, Xiong S, Chao S, et al. Ppargamma gene c161t substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:13.PubMedCrossRef
23.
Zurück zum Zitat Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma c161→t polymorphism and coronary artery disease. Cardiovasc Res. 1999;44(3):588–94.PubMedCrossRef Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma c161→t polymorphism and coronary artery disease. Cardiovasc Res. 1999;44(3):588–94.PubMedCrossRef
24.
Zurück zum Zitat Yilmaz-Aydogan H, Kurnaz O, Kurt O, et al. Effects of the pparg p12a and c161t gene variants on serum lipids in coronary heart disease patients with and without type 2 diabetes. Mol Cell Biochem. 2011;358(1–2):355–63.PubMedCrossRef Yilmaz-Aydogan H, Kurnaz O, Kurt O, et al. Effects of the pparg p12a and c161t gene variants on serum lipids in coronary heart disease patients with and without type 2 diabetes. Mol Cell Biochem. 2011;358(1–2):355–63.PubMedCrossRef
25.
Zurück zum Zitat Zafarmand MH, Van Der Schouw YT, Grobbee DE, et al. Peroxisome proliferator-activated receptor gamma-2 p12a polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag. 2008;4(2):427–36.PubMed Zafarmand MH, Van Der Schouw YT, Grobbee DE, et al. Peroxisome proliferator-activated receptor gamma-2 p12a polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag. 2008;4(2):427–36.PubMed
26.
Zurück zum Zitat Zhou X, Chen J, Xu W. Association between c1431t polymorphism in peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in Chinese Han population. Mol Biol Rep. 2012;39(2):1863–8.PubMedCrossRef Zhou X, Chen J, Xu W. Association between c1431t polymorphism in peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in Chinese Han population. Mol Biol Rep. 2012;39(2):1863–8.PubMedCrossRef
Metadaten
Titel
The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease
verfasst von
Saidan Ding
Leping Liu
Qǐ-Chuan Zhuge
Zhen Yu
Xing Zhang
Jieya Xie
Weilong Hong
Silu Wang
Yunxiu Yang
Bicheng Chen, MD
Publikationsdatum
01.10.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0223-0

Weitere Artikel der Ausgabe 19-20/2012

Wiener klinische Wochenschrift 19-20/2012 Zur Ausgabe

MUW resarcher of the month

Researcher of the month, Oktober 2012